首页> 外文OA文献 >Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

【2h】

Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

机译：血清生物标志物CEA，CYFRA 21-1，SCC和可溶性EGFR及其配体EGF，TGF-α，HB-EGF的预处理水平在厄洛替尼治疗的非小细胞肺癌患者的预后预测中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Elena Yaiza Romero-Ventosa; Sonia Blanco-Prieto; Ana Lourdes González-Piñeiro; Francisco Javier Rodríguez-Berrocal; Guadalupe Piñeiro-Corrales; María Páez de la Cadena;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. [J] . Taron M Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第5期

机译：厄洛替尼治疗的EGFR突变晚期非小细胞肺癌患者的治疗前EGFR T790M突变和BRCA1 mRNA表达。
2. 9000 Mutations of EGFR (mEGFR) in tumour tissue and serum DNA from stage IV non-small-cell lung cancer (NSCLC) patients (p) prospectively treated with erlotinib [J] . R.Rosell, B.Massuti, M.Cobo, European Journal of Cancer Supplements . 2009,第2期

机译：埃洛替尼前瞻性治疗的IV期非小细胞肺癌（NSCLC）患者（p）的肿瘤组织和血清DNA中的9000 EGFR（mEGFR）突变（p）
3. 6529 POSTER 14-3-3s and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations [J] . S.Fernanda, J.L.Ramírez, N.Reguart, European Journal of Cancer Supplements . 2007,第4期

机译：厄洛替尼治疗的非小细胞肺癌（NSCLC）EGFR突变患者的血清中6529 POSTER 14-3-3s和带有叉头和无名指（CHFR）甲基化的检查点
4. Development of EGFR-Targeting Nanomedicine for Effectively and Noninvasively Treats Lung Cancer Patients by Aerosol Delivery [C] . Ching-Li Tseng, Yueh-Hsiu Wu, Su-Wen Yu, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：EGFR靶向纳米药物的开发，可通过气雾剂有效无创地治疗肺癌患者
5. Pretreatment levels of the serum biomarkers CEA CYFRA 21–1 SCC and the soluble EGFR and its ligands EGF TGF-alpha HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients [O] . Elena Yaiza Romero-Ventosa, Sonia Blanco-Prieto, Ana Lourdes González-Piñeiro, -1

机译：血清生物标志物CEACYFRA 21-1SCC和可溶性EGFR及其配体EGFTGF-αHB-EGF的预处理水平在厄洛替尼治疗的非小细胞肺癌患者的预后预测中
6. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations [O] . Reguart Noemi, Porta Rut, Cantos Blanca, 2007

机译：P2-092：厄洛替尼治疗的具有EGFR突变的非小细胞肺癌（NSCLC）患者（p）的血清中叉状和无名指（CHFR）甲基化为14-3-3 sigma和检查点

Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

著录项

相似文献

相关主题

期刊订阅